Severe drug-induced hypersensitivity syndrome with a shared HLA-B allele

We describe the first reported cases of phenytoin-related drug-induced hypersensitivity syndrome in unrelated Indigenous Australians with the same HLA-B*56:02 allele. These patients shared common clinical and pathological features, and all three were found to have the otherwise rare HLA-B allele, which might represent a novel genetic susceptibility factor for this syndrome.

Clinical records

Patient 1

A 32-year-old Indigenous man from a remote Western Australian community presented with a fever, diffuse papular rash and oral ulceration, and a productive cough of 2 weeks’ duration. He was admitted to the intensive care unit (ICU) for respiratory failure and hypotension. Phenytoin 300 mg daily had been prescribed 3 weeks earlier for alcohol-associated seizures. He remained febrile with persistent respiratory failure, and after 10 days he developed profuse diarrhoea and transient hepatitis. Abdominal imaging results were normal and screening tests for bloodstream infections and autoimmune disease were negative. Colonoscopy showed severely inflamed, edematous mucosa and confluent ulceration, with histological evidence of widespread mucosal loss and granulation tissue overlying inflamed superficial submucosa with prominent cytomegalovirus (CMV) inclusions (Box 1 and Box 2).

It was discovered that he had attended a different hospital 2 years earlier with a desquamating rash, oral ulceration, peripheral eosinophilia, lymphadenopathy and prolonged fever after starting phenytoin therapy. Delayed-onset features had included diarrhoea (with colonic CMV inclusions) and hepatitis. There was serological and polymerase chain reaction (PCR) evidence of human herpesvirus 6 (HHV-6) reactivation. A liver biopsy had shown features of drug hypersensitivity. After withdrawal of phenytoin treatment and starting treatment with prednisolone and valganciclovir, he had been discharged 47 days after admission, and had been advised to avoid phenytoin.

When this previous hospitalisation history came to our attention, we discontinued phenytoin treatment and started corticosteroid and ganciclovir treatment. There was no evidence of HHV-6 reactivation. CMV DNA was initially detected in colonic biopsies (on day 8), and subsequently in whole blood and stool samples (in week 5). The patient’s profuse diarrhoea persisted despite ganciclovir, opiates and octreotide treatment, and after 8 weeks it was complicated by recurrent bleeding requiring alternate-day blood transfusions. A further colonoscopy to investigate the bleeding showed regenerative, hypervascular colonic mucosa with reduced ulceration. After 11 weeks in the intensive care unit, the patient deteriorated with refractory hypotension and worsening respiratory failure, and died 2 days later.

Patient 2

A 33-year-old Indigenous man from Perth, Western Australia, presented with a generalised desquamating rash without mucosal involvement, and fever and abdominal pain of 4 weeks’ duration, 3 months after commencing phenytoin 300 mg daily for alcohol-related seizures. Investigations revealed hepatitis and eosinophilia, and gastroscopy showed gastric ulceration with prominent CMV viral inclusions. CMV and HHV-6 DNA were also detected in whole blood. Phenytoin treatment was ceased and corticosteroid and ganciclovir treatment was started, followed by oral valganciclovir until the CMV viraemia resolved. The patient recovered fully.

Patient 3

A 43-year-old Indigenous woman from a remote Northern Territory community presented with a cerebral abscess requiring surgical drainage and intravenous phenytoin prophylaxis 300 mg daily. She had an initially uneventful recovery until 2 weeks postoperatively, when she became progressively hypoxaemic, with bilateral pulmonary infiltrates. She developed a desquamating rash, hepatitis, eosinophilia and diarrhoea. Phenytoin treatment was ceased and she was admitted to the ICU. She developed progressive multiple organ failure and died 10 days later, despite receiving maximal supportive therapy.

Discussion

For all three patients, human leukocyte antigen (HLA) typing revealed HLA-B*56:02 as a common allele (including one patient with an HLA-B*56:02 homozygous allele). Although this allele is widely distributed globally, it is generally rare. Among Indigenous Australians, localised areas of high prevalence (more than 10%) have been found in central Australia, although previous studies of Indigenous populations in WA, and in Arnhem Land in the...
Northern Territory, suggest a population prevalence of less than 2%. Within the Australian Bone Marrow Donor Registry (which has recently been enriched by involvement of Indigenous Australian donors), HLA-B*56:02 is present in 0.6% (173/29 067) of donors who have had DNA sequencing performed at HLA-B.

The occurrence of this HLA-B allele in three unrelated cases therefore appears exceptionally unlikely to have occurred by chance alone, suggesting that it may be appropriate to add it to an existing list of HLA-B alleles marking genetic susceptibility to drug hypersensitivity syndromes. This list includes HLA-B*57:01 (hypersensitivity to abacavir and flucloxacinill), B*58:01 (allopurinol), B*15:02 (carbamazepine) and B*35:05 (nevirapine).

These three cases are in keeping with diagnostic criteria for drug-induced hypersensitivity syndrome (DIHS) (formerly known as drug reaction with eosinophilia and systemic symptoms [DRESS] syndrome). Criteria include:

- delayed-onset rash 2–6 weeks after initial drug exposure
- haematological abnormalities (eosinophilia and/or atypical lymphocytosis)
- systemic features with prolonged fever and/or lymphadenopathy as well as organ involvement (most frequently hepatitis, but also gastrointestinal, lung and kidney involvement).

Expanded diagnostic criteria acknowledge the diagnostic value of prolonged clinical symptoms 2 weeks after drug discontinuation. The prolonged clinical symptoms may reflect the role of herpesvirus reactivation in the perpetuation of hypersensitivity responses. Anticonvulsants are frequently implicated in DIHS, and in the case of carbamazepine-associated DIHS, there is evidence of HLA-associated susceptibility (in this case, with HLA-A*31:01).

Patients may develop two or three features of the syndrome at one time, with symptom resolution in one organ often followed by development of symptoms in another organ system. DIHS and Stevens–Johnson syndrome share some features, including their delayed onset and prolonged course. However, mucocutaneous signs are more common in Stevens–Johnson syndrome, especially in the mouth and eyes, but facial oedema and small pustules are more typical of DIHS. In contrast, herpesvirus reactivation, hepatitis and other visceral involvement are more strongly associated with DIHS.

One unusual aspect of DIHS is the relationship between immune-mediated drug reactions and the reactivation of herpesviruses infection. This is particularly so for HHV-6 as well as CMV and Epstein–Barr virus (EBV), which may explain why organ involvement and systemic inflammation may be delayed in onset and prolonged after discontinuation of the offending drug. Real-time PCR analyses of subjects with DIHS have shown that various herpesviruses can sequentially reactivate during the syndrome, often initially HHV-6 or EBV, then HHV-7 and later CMV. Such a cascade of sequential reactivation is also seen in graft-versus-host disease. It seems likely in these cases that HLA-B*56:02 is involved in binding and presenting phenytoin (or a metabolite of phenytoin) to T-cells, although there are several possible mechanisms for HLA-restricted immune responses to drugs. In the context of DIHS, there is additional evidence that antiviral T-cells may also be affected by this process, so that delayed tissue injury may be mediated by pro-inflammatory antiviral immune responses rather than by the viruses themselves. The immunological basis for these reactions — and the temporal relationships between virus-specific and drug-specific immune responses — have not been completely elucidated. However, it is notable that B-cell depletion and hypogammaglobulinemia are also found early in the clinical course of DIHS. One possible explanation for these B-cell abnormalities, in a syndrome that is otherwise thought to involve drug-specific T-cell responses, is that regulatory T-cell populations are preferentially involved in the early immune response.

Mortality associated with DIHS is 10%–20%. Diagnostic awareness is therefore critical — including awareness of the potential for both delayed-onset and prolonged manifestations that may otherwise be viewed as atypical for a drug hypersensitivity syndrome. Previous experience with HLA-associated drug hypersensitivity reactions has demonstrated the contribution of genetic testing strategies towards improved vigilance and diagnostic accuracy. We believe that the novel finding of three patients with the same HLA-B*56:02 allele warrants further investigation in an expanded case series.

Acknowledgement: We thank Hooi Ee for help in reviewing and preparing this article.

Competing interests: No relevant disclosures.
Received 11 Mar 2012, accepted 2 Aug 2012.


